Results 161 to 170 of about 176,622 (333)

A Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft (PDOX) Mouse Model Is Sensitive to Bevacizumab and Vinorelbine, Regressed by Eribulin and Resistant to Olaparib [PDF]

, 2020
Jun Yamamoto, Takuya Murata, Yoshihiko Tashiro, Takashi Higuchi, Norihiko Sugisawa, Hiroto Nishino, Sachiko Inubushi, Yu Sun, HYEIN LIM, Kentaro Miyake, Atsushi Hongo, Tsunehisa Nomura, Wataru Saitoh, Takuya Moriya, Hirokazu Tanino, CHIHIRO HOZUMI, Michael Bouvet, Shree Ram Singh, Itaru Endo, Robert M. Hoffman   +19 more
openalex   +1 more source

Figure S7 from Matrix Stiffness Triggers Lipid Metabolic Cross-talk between Tumor and Stromal Cells to Mediate Bevacizumab Resistance in Colorectal Cancer Liver Metastases [PDF]

, 2023
Yannan Zheng, Rui Zhou, Jianan Cai, Nanyan Yang, Zhaowei Wen, Zhihua Zhang, Huiying Sun, Genjie Huang, Yijin Guan, Na Huang, Min Shi, Yulin Liao, Jianping Bin, Wangjun Liao   +13 more
openalex   +1 more source

Advances in the Diagnosis, Treatment, and Management of Liver Nodules: A Comprehensive Review

Portal Hypertension &Cirrhosis, EarlyView.
Liver nodules commonly occur due to various causes, some of which are malignant or may undergo malignant transformation, leading to disease progression or delayed detection in clinical practice. The widespread use of imaging methods has increased the detection rate of liver nodules. Furthermore, precision medicine techniques and artificial intelligence
Chang Gao, Dongyang Chen, Youpeng Chen
wiley   +1 more source

Clinical application of boron neutron capture therapy for cancer treatment: A systematic review

Precision Radiation Oncology, EarlyView.
This review provides an overview of the development of boron‐containing drugs, and the progress made in clinical studies of BNCT, in order to promote the research and development of accelerator‐based neutron sources, increase the tumor‐targeting of boron drugs, and improve BNCT efficacy to treat malignancies.
Ling Zhou, Yuming Chen, Meng Peng, Xiumao Yin, Huanqing Liang, Jieming Mo, Wan Zhang, Zhigang Liu   +7 more
wiley   +1 more source

[Initial Treatment of Aumolertinib in Combination with Bevacizumab for Advanced NSCLC with Primary EGFR T790M Mutation: A Report of Three Cases and Literature Review]. [PDF]

, 2023
Xue Yang, Fanlu Meng, Diansheng Zhong
openalex   +1 more source

A sample size analysis of a mathematical model of longitudinal tumor volume and progression‐free survival for Bayesian individual dynamic predictions in recurrent high‐grade glioma

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 495-509, March 2025.
Abstract Patients with recurrent high‐grade glioma (rHGG) have a poor prognosis with median progression‐free survival (PFS) of <7 months. Responses to treatment are heterogenous, suggesting a clinical need for prognostic models. Bayesian data analysis can exploit individual patient follow‐up imaging studies to adaptively predict the risk of progression.
Daniel J. Glazar, Solmaz Sahebjam, Hsiang‐Husan M. Yu, Dung‐Tsa Chen, Menal Bhandari, Heiko Enderling   +5 more
wiley   +1 more source

Efficacy and safety of neoadjuvant bevacizumab plus chemotherapy in locally advanced gastric cancer patients: a retrospective, comparative study

World Journal of Surgical Oncology
Objective The clinical benefits of neoadjuvant bevacizumab plus chemotherapy in locally advanced gastric cancer patients are controversial. This study intended to evaluate the efficacy and safety of neoadjuvant bevacizumab plus chemotherapy in these ...
Bin Yin, Wei Luo
doaj   +1 more source

Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial. [PDF]

CA Cancer J Clin
Abstract Although poly(adenosine diphosphate‐ribose) polymerase inhibitors (PARPis) and bevacizumab were approved as first‐line maintenance for advanced ovarian cancer (OC), evidence comparing this combination with PARPi monotherapy, especially in BRCA‐mutated/homologous recombination‐deficient (HRD) patients, is lacking.
Wu L, Wang J, Li Q, Wang D, Zhang C, Tang J, Zhang G, Hao M, Yao D, Gao Q, Zhang Y, An R, Yin R, Wang L, Xia B, Zhou Q, Yang H, Zhu J, Jiang K, Chen Z, Wu Q, Duan W, Huang Y, Zhang H, Wei S, Li G, Meng Y, Wang K, Yang X, Huang X, Pan L, Yu J, Lou G, Zhang Y, Zhou H, Guo X, Yang H, Cheng X, Li X, Wang W, Zhao H, Li Y, Yang Y, Lin A, Cheng W, Chen L, Xie X, Di W, Hu Y, Chen M, Wen H, Cai L, Wu X, Lin Z, Wang Q, Yang X, Li N.   +56 more
europepmc   +2 more sources

Comparison of antiangiogenic agents (ranibizumab, aflibercept, bevacizumab and ziv-aflibercept) in the therapeutic response to the exudative form of age-related macular degeneration according to the treat-and-extend protocol- true head-to-head study [PDF]

Tereza Cristina Moreira Kanadani, Neiffer Nunes Rabelo, Denise Takahashi, Lucas M. Magalhães, Michel Eid Farah   +4 more
openalex   +1 more source

743MO Efficacy and safety of QL1706 plus paclitaxel and cisplatin/carboplatin +/- bevacizumab (Bev) as 1L treatment in recurrent or metastatic cervical cancer (r/mCC): A single-arm, multicenter phase II study [PDF]

, 2023
Nan Liu, Zijing Yang, Ding Tang, Hanmei Lou, Kai Zhang, Hui Cao, Dehui Zou, Xiaofeng Zhang, Song Xue, Xun Kang, Dong Wang   +10 more
openalex   +1 more source